CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.

Françoise Solly; Fanny Angelot; Richard Garand; Christophe Ferrand; Estelle Seillès; Françoise Schillinger; Agnès Decobecq; Maryse Billot; Fabrice Larosa; Emmanuel Plouvier; Eric Deconinck; Faezeh Legrand; Philippe Saas; Pierre-Simon Rohrlich; Francine Garnache-Ottou

doi:10.1002/cyto.a.21162

Journal articles

CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.

Françoise Solly ^{1, 2} Fanny Angelot ^{2, 3} Richard Garand ⁴ Christophe Ferrand ^{2, 3} Estelle Seillès ^{2, 3} Françoise Schillinger ² Agnès Decobecq ² Maryse Billot ² Fabrice Larosa ⁵ Emmanuel Plouvier ⁶ Eric Deconinck ^{3, 5} Faezeh Legrand ⁵ Philippe Saas ^{2, 3} Pierre-Simon Rohrlich ^{3, 6} Francine Garnache-Ottou ^{2, 3, *}

* Corresponding author

1 Laboratoire d'Hematologie

2 Laboratoire d'hémostase, cytologie, plateforme de biomonitoring

3 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)

4 Laboratoire d'Hematologie

5 Service d'hématologie

6 Service de pédiatrie

Abstract : Minimal residual disease (MRD) has emerged as a major prognostic factor for monitoring patients with B-lineage acute lymphoblastic leukemia (B-ALL). The quantification of MRD by flow cytometry (FC) is based on the identification of a leukemia-associated phenotype (LAP). Because phenotypic switch is common during treatment, multiple LAPs must be available and used for MRD detection over time. We evaluated the potential usefulness of CD304 as a new marker for monitoring MRD. CD304 was expressed in 48% of B-ALL (24/50) with discriminative fluorescence intensity compared with CD304-negative normal B-cell precursors (n = 15). The sensitivity of CD304-based MRD detection reached 10(-4), as with some of established LAPs. The stability of CD304 expression evaluated during therapy and at relapse confirms the usefulness of this marker for MRD quantification. Finally, CD304 was repeatedly expressed in patients with TEL-AML1 gene rearrangement, which warrants further investigation on its potential relevance as a prognosis marker or therapeutic target.

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Immunology

Complete list of metadata

https://www.hal.inserm.fr/inserm-00799678
Contributor : Philippe Saas Connect in order to contact the contributor
Submitted on : Tuesday, March 12, 2013 - 3:07:00 PM
Last modification on : Monday, December 6, 2021 - 3:10:24 PM

CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.

Links full text

Identifiers

Collections

Citation

Export

Metrics

524

CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry.

Links full text

Identifiers

Collections

Citation

Export

Share

Metrics

524